BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Kubo A, Hashimoto H, Takahashi N, Yamada Y. Biomarkers of skin toxicity induced by anti-epidermal growth factor receptor antibody treatment in colorectal cancer. World J Gastroenterol 2016; 22(2): 887-894 [PMID: 26811634 DOI: 10.3748/wjg.v22.i2.887]
URL: https://www.wjgnet.com/1948-5204/full/v22/i2/887.htm
Number Citing Articles
1
Giovanni Damiani, Ausilia Manganoni, Simone Cazzaniga, Luigi Naldi. Survey of cutaneous adverse reactions to targeted cancer therapies: value of dermatological adviceGiornale Italiano di Dermatologia e Venereologia 2020; 155(5) doi: 10.23736/S0392-0488.18.06033-9
2
W. W. B. de Kort, S. Spelier, L. A. Devriese, R. J. J. van Es, S. M. Willems. Predictive Value of EGFR-PI3K-AKT-mTOR-Pathway Inhibitor Biomarkers for Head and Neck Squamous Cell Carcinoma: A Systematic ReviewMolecular Diagnosis & Therapy 2021; 25(2): 123 doi: 10.1007/s40291-021-00518-6
3
George Kafatos, Sabada Dube, Peter Burdon, Gaston Demonty, Alain Flinois, Marjorie Leclerc, Kimberly Lowe, Maurille Feudjo-Tepie, Siegfried Segaert. Management of EGFR Inhibitor-induced Skin Toxicity and Factors Impacting Patients’ Adherence to Skin Toxicity Treatment: Health Care Provider and Patient Surveys in European Oncology CentersClinical Colorectal Cancer 2020; 19(2): 100 doi: 10.1016/j.clcc.2020.01.001
4
Matthias F. Froelich, Sebastian Stintzing, Jörg Kumbrink, Thomas G.P. Grünewald, Ulrich Mansmann, Volker Heinemann, Thomas Kirchner, Andreas Jung. The DNA-polymorphism rs849142 is associated with skin toxicity induced by targeted anti-EGFR therapy using cetuximabOncotarget 2018; 9(54): 30279 doi: 10.18632/oncotarget.25689
5
J. Fernández-Mateos, R. Seijas-Tamayo, R. Mesía, M. Taberna, M. Pastor Borgoñón, E. Pérez-Ruiz, J.C. Adansa Klain, S. Vázquez Fernández, E. del Barco Morillo, A. Lozano, R. González Sarmiento, J.J. Cruz-Hernández. Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish populationOral Oncology 2016; 63: 38 doi: 10.1016/j.oraloncology.2016.10.006
6
Yusuf Acikgoz, Oznur Bal, Gokhan Ucar, Ayse Durnali, Yakup Ergun, Merve Dirikoc, Selin Akturk Esen, Mutlu Dogan. Is there any clinical or laboratory predictive factor for cetuximab-induced skin toxicity?Expert Opinion on Drug Safety 2021; 20(5): 611 doi: 10.1080/14740338.2021.1893304
7
Yoshitaka Saito, Kazuki Uchiyama, Yoh Takekuma, Yoshito Komatsu, Mitsuru Sugawara. Evaluation of the additional prophylactic effect of topical steroid ointment to systemic minocycline against anti-epidermal growth factor antibody-induced skin toxicities in metastatic colorectal cancer treatmentSupportive Care in Cancer 2024; 32(1) doi: 10.1007/s00520-023-08195-3
8
C. Dessinioti, C. Antoniou, A.J. Stratigos. From basal cell carcinoma morphogenesis to the alopecia induced by hedgehog inhibitors: connecting the dotsBritish Journal of Dermatology 2017; 177(6): 1485 doi: 10.1111/bjd.15738
9
Yoshitaka Saito, Kazuki Uchiyama, Yoh Takekuma, Yoshito Komatsu, Mitsuru Sugawara. Risk factor analysis for anti-epidermal growth factor receptor monoclonal antibody–induced skin toxicities in real-world metastatic colorectal cancer treatmentSupportive Care in Cancer 2023; 31(8) doi: 10.1007/s00520-023-07973-3
10
Júlia Kanaan Recuero, Joana Roberta Fitz, Andrea Abe Pereira, Renan Rangel Bonamigo. EGFR inhibitors: clinical aspects, risk factors and biomarkers for acneiform eruptions and other mucosal and cutaneous adverse effectsAnais Brasileiros de Dermatologia 2023; 98(4): 429 doi: 10.1016/j.abd.2022.10.004
11
Ekaterina V. Orlova, Olga Yu. Olisova. The role of polymorphism of the epidermal growth factor gene in the formation of severe manifestations of skin toxicity caused by the use of EGFR inhibitorsRussian Journal of Skin and Venereal Diseases 2023; 26(5): 431 doi: 10.17816/dv108023
12
Mario E. Lacouture, Milan Anadkat, Aminah Jatoi, Tamer Garawin, Chet Bohac, Edith Mitchell. Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic ReviewClinical Colorectal Cancer 2018; 17(2): 85 doi: 10.1016/j.clcc.2017.12.004